Clinical trial · Interventional
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
NCT00135161CI-TRIAL-00062565completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this trial is to study fluorodeoxyglucose-positron emission tomography (FDG-PET)-based dose escalation using intensity modulated radiation therapy (IMRT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Neoplasms | Head and Neck Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT). | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intensity modulated radiation therapy (IMRT).
- interventionNames
- Procedure: FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
Primary outcomes (2)
- measure
- Acute toxicity during radiotherapy until 3 months after the end of the radiotherapy
- timeFrame
- until 3 months after the end of the radiotherapy
- measure
- Observation of chronic toxicity
- timeFrame
- until 3 months after the end of the radiotherapy
Secondary outcomes (3)
- measure
- Therapy response (2-4 months after end of radiotherapy)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a proven histological squamous cell carcinoma of the larynx (only T3-4 NO or Tany N+), hypopharynx, oropharynx * Patients who did not undergo surgery for the primary tumor location * Patients with a Karnofsky performance score of 70% or more * Written informed consent for participation in this trial Exclusion Criteria: * Other malignancy except for non-melanoma skin cancer * Prior irradiation to the head and neck region
References
Publications (0)
Data not yet available
No reference posted for this study.